Mga Batayang Estadistika
| CIK | 1872812 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to TC Biopharm (Holdings) Plc - Depositary Receipt (Common Stock)
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| September 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2025 Commission File Number 001-41231 TC BIOPHARM (HOLDINGS) PLC (Translation of registrant’s name into English) Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR Scotland, United K |
|
| August 5, 2025 |
Exhibit 99.2 TC BIOPHARM (HOLDINGS) PLC Form of Proxy for the Annual General Meeting This proxy is solicited by the Board of Directors I/We, (name in full in block capitals) of being a member/members of TC BioPharm (Holdings) plc (the “Company”) hereby appoint the Chair of the meeting (see note 1 below) as my/our proxy to attend, speak and vote for me/us and on my/our behalf in relation to all Ord |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2025 Commission File Number 001-41231 TC BIOPHARM (HOLDINGS) PLC (Translation of registrant’s name into English) Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR Scotland, United King |
|
| August 5, 2025 |
Exhibit 99.3 |
|
| August 5, 2025 |
Exhibit 99.1 TC BIOPHARM (HOLDINGS) PLC Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR United Kingdom (Incorporated and registered in Scotland with registered number SC713098) THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to the action to be taken, please seek your own financial advice from your stockbroker, solicitor, accountant or other appr |
|
| May 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number 001-41231 TC BIOPHARM (HOLDINGS) PLC (Translation of registrant’s name into English) Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR Scotland, United King |
|
| May 9, 2025 |
TC BIOPHARM (HOLDINGS) PLC Insider Trading Policy ADOPTED FEBRUARY 07, 2022 Exhibit 19.1 TC BIOPHARM (HOLDINGS) PLC Insider Trading Policy ADOPTED FEBRUARY 07, 2022 Policy Under United States securities laws, it is a crime to buy or sell securities of a company (including stocks or bonds) while in possession of material, non-public information about the company. Furthermore, it is a crime to pass on such information to others who use it for personal profit if the informat |
|
| May 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT O |
|
| May 9, 2025 |
Exhibit 13.1 Certification by the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report on Form 20-F of TC BioPharm (Holdings) plc (the “Company”) for the fiscal year ended December 31, 2024 as filed with the Securities and Exchange Commission on the d |
|
| May 9, 2025 |
Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Martin Thorp, certify that: 1. I have reviewed this annual report on Form 20-F of TC BioPharm (Holdings) plc (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statemen |
|
| May 9, 2025 |
TC BIOPHARM (HOLDINGS) PLC CLAWBACK POLICY Exhibit 97.1 TC BIOPHARM (HOLDINGS) PLC CLAWBACK POLICY I. Purpose and Scope The Board of Directors (the “Board”) of the Company believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board has therefore adopted this |
|
| May 9, 2025 |
Exhibit 16.1 May 9, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by TC BioPharm (Holdings) plc under Item 16F of its Form 20-F for the fiscal year ended December 31, 2024. We agree with the statements concerning our Firm in such Form 20-F; we are not in a position to agree or disagree with other statements of TC Bio |
|
| May 9, 2025 |
Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Bryan Kobel, certify that: 1. I have reviewed this annual report on Form 20-F of TC BioPharm (Holdings) plc (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number 001-41231 TC BIOPHARM (HOLDINGS) PLC (Translation of registrant’s name into English) Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR Scotland, United King |
|
| May 6, 2025 |
Exhibit 99.3 |
|
| May 6, 2025 |
Exhibit 99.1 TC BioPharm (Holdings) plc Maxim 1, 2 Parklands Way, Holytown, Motherwell, Scotland ML1 4WR Registered Company No. SC713098 May 6, 2025 Dear Shareholder General Meeting of the Shareholders (‘Members’) of TC BioPharm (Holdings) plc (“General Meeting” or “GM”) Shareholders in the Company (also referred to as ‘Members’) We are writing to provide details of a General Meeting of TC BioPhar |
|
| May 6, 2025 |
Exhibit 99.2 TC BIOPHARM (HOLDINGS) PLC Form of Proxy for a General Meeting This proxy is solicited by the Board of Directors I/We, (name in full in block capitals) of being a member/members of TC BioPharm (Holdings) plc (the “Company”) hereby appoint the Chair of the meeting (see note 1 below) as my/our proxy to attend, speak and vote for me/us and on my/our behalf in relation to all Ordinary sha |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 001-41231 NOTIFICATION OF LATE FILING ☐ Form 10-K ☒ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form 20-F ☐ Transition Report on Form N-SAR |
|
| March 21, 2025 |
TCBP Announces Transition from Nasdaq to OTC Markets Exhibit 99.1 TCBP Announces Transition from Nasdaq to OTC Markets EDINBURGH, Scotland, March 21, 2025— TC BioPharm (Holdings) PLC (“TC BioPharm” or the “Company”), (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that on March 20, 2025, it received notice that the Nasdaq Hearings Pane |
|
| March 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number 001-41231 TC BIOPHARM (HOLDINGS) PLC (Translation of registrant’s name into English) Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR Scotland, United Ki |
|
| February 10, 2025 |
TCBP to Implement ADS Ratio Change Exhibit 99.1 TCBP to Implement ADS Ratio Change EDINBURGH, Scotland, Feb. 5, 2025 — TC BioPharm (Holdings) PLC (“TC BioPharm” or the “Company”) (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it will change its ratio of its American Depositary Shares (“ADSs”) to ordinary shares |
|
| February 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission File Number 001-41231 TC BIOPHARM (HOLDINGS) PLC (Translation of registrant’s name into English) Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR Scotland, United |
|
| February 10, 2025 |
Exhibit 99.2 TC BioPharm (Holdings) plc Maxim 1,2 Parklands Way, Maxim Park, Eurocentral, ML1 4WR Tel: 0141 433 7557 | Email: [email protected] February 10, 2025 VIA OVERNIGHT MAIL The Holders of Warrants to Purchase American Depositary Shares issued pursuant to the terms of that certain warrant agent agreement, dated February 10, 2022 (collectively, the “Holders”): To Whom It May Concern: You a |
|
| January 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number 001-41231 TC BIOPHARM (HOLDINGS) PLC (Translation of registrant’s name into English) Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR Scotland, United |
|
| January 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number 001-41231 TC BIOPHARM (HOLDINGS) PLC (Translation of registrant’s name into English) Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR Scotland, United |
|
| January 8, 2025 |
Exhibit 99.1 |
|
| December 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number 001-41231 TC BIOPHARM (HOLDINGS) PLC (Translation of registrant’s name into English) Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR Scotland, United |
|
| December 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number 001-41231 TC BIOPHARM (HOLDINGS) PLC (Translation of registrant’s name into English) Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR Scotland, United |
|
| December 17, 2024 |
AT THE MARKET OFFERING AGREEMENT Exhibit 99.1 AT THE MARKET OFFERING AGREEMENT December 16, 2024 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: TC BioPharm (Holdings) plc, a public limited company incorporated in Scotland pursuant to the Companies Act 2006, as amended with company number SC713098 (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC ( |
|
| December 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number 001-41231 TC BIOPHARM (HOLDINGS) PLC (Translation of registrant’s name into English) Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR Scotland, United |
|
| December 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number 001-41231 TC BIOPHARM (HOLDINGS) PLC (Translation of registrant’s name into English) Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR Scotland, United |
|
| December 16, 2024 |
Up to $14,000,000 Ordinary Shares Represented by American Depositary Shares Filed Pursuant to Rule 424(b)(5) Registration No. 333-283507 PROSPECTUS SUPPLEMENT (To Prospectus Dated December 11, 2024) Up to $14,000,000 Ordinary Shares Represented by American Depositary Shares We have entered into an At The Market Offering Agreement dated as of December 16, 2024 (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (the “Sales Agent” or “Wainwright”), relating to the sale |
|
| December 16, 2024 |
Exhibit 99.2 TC BIOPHARM (HOLDINGS) PLC Form of Proxy for a General Meeting This proxy is solicited by the Board of Directors I/We, (name in full in block capitals) of being a member/members of TC BioPharm (Holdings) plc (the “Company”) hereby appoint the Chair of the meeting (see note 1 below) as my/our proxy to attend, speak and vote for me/us and on my/our behalf in relation to all Ordinary sha |
|
| December 16, 2024 |
TC BIOPHARM (HOLDINGS) PLC Form of Proxy for ADS Holders Exhibit 99.3 TC BIOPHARM (HOLDINGS) PLC Form of Proxy for ADS Holders |
|
| December 16, 2024 |
Exhibit 99.1 TC BioPharm (Holdings) plc Maxim 1, 2 Parklands Way, Holytown, Motherwell, Scotland ML1 4WR Registered Company No. SC713098 December 13, 2024 Dear Shareholder General Meeting of the Shareholders (‘Members’) of TC BioPharm (Holdings) plc (“General Meeting” or the “GM”) We are writing to provide details of a GM of TC BioPharm (Holdings) plc (the “Company”) to be held as a physical meeti |
|
| December 9, 2024 |
TC BIOPHARM (HOLDINGS) PLC Maxim 1, 2 Parklands Way Holytown, Motherwell ML1 4WR Scotland, United Kingdom December 9, 2024 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N. |
|
| November 27, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form F-3 TC Biopharm (Holdings) plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Equity Ordinary Shares, par value £0. |
|
| November 27, 2024 |
As filed with the Securities and Exchange Commission on November 27, 2024 As filed with the Securities and Exchange Commission on November 27, 2024 Registration No. |
|
| November 27, 2024 |
Exhibit 4.7 INDENTURE, dated as of [ ], by and between TC Biopharm (Holdings) plc, a public limited company incorporated in Scotland pursuant to the Companies Act 2006 (the “Company”), and [ ], as trustee (the “Trustee”): WHEREAS, for its lawful corporate purposes, the Company has duly authorized the execution and delivery of this Indenture to provide for the issuance of subordinated debt securiti |
|
| November 27, 2024 |
Exhibit 4.6 INDENTURE, dated as of [ ], by and between TC Biopharm (Holdings) plc, a public limited company incorporated in Scotland pursuant to the Companies Act 2006 (the “Company”), and [ ], as trustee (the “Trustee”): WHEREAS, for its lawful corporate purposes, the Company has duly authorized the execution and delivery of this Indenture to provide for the issuance of debt securities (hereinaft |
|
| November 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of November 2024 Commission File No. 001-41231 TC BIOPHARM (HOLDINGS) PLC (Exact Name of Registrant as Specified in Its Charter) Scotland N/A (State or other jurisdiction of incorporation or organ |
|
| November 25, 2024 |
Management’s Discussion and Analysis of Financial Condition and Results of Operations Exhibit 99.2 Management’s Discussion and Analysis of Financial Condition and Results of Operations The following discussion and analysis should be read in conjunction with the unaudited condensed consolidated financial statements and related notes included elsewhere in this Report and our audited financial statements and related notes thereto included in our Annual Report on Form 10-K for the year |
|
| November 25, 2024 |
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS Exhibit 99.1 Unless we state otherwise or the context otherwise requires, the terms “TC Biopharm,”, “TCB”, “we,” “us,” “our” and the “Company” refer to TC Biopharm (Holdings) plc. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Report contains forward-looking statements that involve risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of th |
|
| November 14, 2024 |
SC 13G/A 1 armistice-tcbp093024a2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* TC BIOPHARM (HOLDINGS) PLC (Name of Issuer) American Depositary Shares, each representing twenty Ordinary Share, nominal value £0.01 per share (Title of Class of Securities) 87807D509 (CUSIP Number) September 30, 202 |
|
| October 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number 001-41231 TC BIOPHARM (HOLDINGS) PLC (Translation of registrant’s name into English) Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR Scotland, Unite |
|
| August 30, 2024 |
Exhibit 10.3 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of August 28, 2024, between TC BioPharm (Holdings) plc, a public limited company incorporated in Scotland pursuant to the Companies Act 2006, as amended with company number SC713098 (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors |
|
| August 30, 2024 |
TC BioPharm Announces Closing of Upsized $6.0 Million Public Offering Exhibit 99.1 TC BioPharm Announces Closing of Upsized $6.0 Million Public Offering EDINBURGH, Scotland, Aug. 28, 2024 /PRNewswire/ — TC BioPharm (Holdings) PLC (“TC BioPharm” or the “Company”) (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced the closing of its previously announced pub |
|
| August 30, 2024 |
Exhibit 10.2 SERIES H WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES TC BIOPHARM (HOLDINGS) PLC Warrant ADSs: Initial Exercise Date: THIS SERIES H WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on |
|
| August 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number 001-41231 TC BIOPHARM (HOLDINGS) PLC (Translation of registrant’s name into English) Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR Scotland, United K |
|
| August 30, 2024 |
Exhibit 10.1 PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES TC BIOPHARM (HOLDINGS) PLC Warrant ADSs: Initial Exercise Date: THIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations |
|
| August 29, 2024 |
Filed Pursuant to Rule 424(b)(4) Registration No. 333-281613 53,558 AMERICAN DEPOSITARY SHARES REPRESENTING 10,711,600 ORDINARY SHARES AND 5,946,442 PRE-FUNDED WARRANTS TO PURCHASE 5,946,442 AMERICAN DEPOSITARY SHARES AND 6,000,000 SERIES H WARRANTS TO PURCHASE 6,000,000 AMERICAN DEPOSITARY SHARES (and 5,946,442 American Depositary Shares representing 1,189,288,400 ordinary shares underlying the P |
|
| August 28, 2024 |
EX-FILING FEES 5 ex107.htm CALCULATION OF FILING FEE TABLES Exhibit 107 Calculation of Filing Fee Tables Form F-1 (Form Type) TC Biopharm (Holdings) PLC (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be pa |
|
| August 28, 2024 |
As filed with the Securities and Exchange Commission on August 28, 2024 F-1MEF 1 formf-1mef.htm As filed with the Securities and Exchange Commission on August 28, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TC BIOPHARM (HOLDINGS) PLC (Exact name of Registrant as specified in its charter) Scotland 8731 Not applicable (State or other jurisdiction of in |
|
| August 26, 2024 |
TC BIOPHARM (HOLDINGS) PLC Maxim 1, 2 Parklands Way Holytown, Motherwell ML1 4WR Scotland, United Kingdom August 26, 2024 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N. |
|
| August 23, 2024 |
Exhibit 4.15 SERIES H WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES TC BIOPHARM (HOLDINGS) PLC Warrant ADSs: Initial Exercise Date: THIS SERIES H WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on |
|
| August 23, 2024 |
As filed with the Securities and Exchange Commission on August 23, 2024 As filed with the Securities and Exchange Commission on August 23, 2024 Registration Statement No. |
|
| August 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number 001-41231 TC BIOPHARM (HOLDINGS) PLC (Translation of registrant’s name into English) Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR Scotland, United K |
|
| August 23, 2024 |
Exhibit 10.21 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2024, between TC BioPharm (Holdings) plc, a public limited company incorporated in Scotland pursuant to the Companies Act 2006, as amended with company number SC713098 (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assi |
|
| August 23, 2024 |
Exhibit 4.14 PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES TC BIOPHARM (HOLDINGS) PLC Warrant ADSs: Initial Exercise Date: THIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations |
|
| August 16, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form F-1 (Form Type) TC Biopharm (Holdings) PLC (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be paid Equity Ordinary Shares, par value £0. |
|
| August 16, 2024 |
As filed with the Securities and Exchange Commission on August 16, 2024 As filed with the Securities and Exchange Commission on August 16, 2024 Registration Statement No. |
|
| August 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number 001-41231 TC BIOPHARM (HOLDINGS) PLC (Translation of registrant’s name into English) Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR Scotland, United K |
|
| August 15, 2024 |
Exhibit 10.1 PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES TC BIOPHARM (HOLDINGS) PLC Warrant ADSs: Initial Exercise Date: August 15, 2024 THIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to |
|
| August 15, 2024 |
TC BioPharm Announces Pricing of $2.0 Registered Direct Offering Exhibit 99.1 TC BioPharm Announces Pricing of $2.0 Registered Direct Offering EDINBURGH, Scotland, Aug. 13, 2024 /PRNewswire/ - TC BioPharm (Holdings) PLC (“TC BioPharm” or the “Company”) (NASDAQ:TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced it has entered into definitive agreement for the |
|
| August 15, 2024 |
Exhibit 10.2 SERIES G WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES TC BIOPHARM (HOLDINGS) PLC Warrant ADSs: Initial Exercise Date: August 15, 2024 THIS SERIES G WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the |
|
| August 15, 2024 |
Exhibit 10.3 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of August 13, 2024, between TC BioPharm (Holdings) plc, a public limited company incorporated in Scotland pursuant to the Companies Act 2006, as amended with company number SC713098 (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors |
|
| August 14, 2024 |
Filed Pursuant to Rule 424(b)(4) Registration No. 333-280659 23,950 AMERICAN DEPOSITARY SHARES REPRESENTING 4,790,000 ORDINARY SHARES AND 1,976,050 PRE-FUNDED WARRANTS TO PURCHASE UP TO 1,976,050 AMERICAN DEPOSITARY SHARES AND 2,000,000 SERIES G WARRANTS TO PURCHASE UP TO 2,000,000 AMERICAN DEPOSITARY SHARES (and 1,976,050 American Depositary Shares representing 395,210,000 ordinary shares underly |
|
| August 9, 2024 |
As filed with the Securities and Exchange Commission on August 9, 2024 As filed with the Securities and Exchange Commission on August 9, 2024 Registration Statement No. |
|
| August 9, 2024 |
Exhibit 4.12 EXHIBIT B PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES TC BIOPHARM (HOLDINGS) PLC Warrant ADSs: Initial Exercise Date: , 2024 THIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject t |
|
| August 9, 2024 |
Exhibit 4.13 EXHIBIT A SERIES G WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES TC BIOPHARM (HOLDINGS) PLC Warrant ADSs: Initial Exercise Date: , 2024 THIS SERIES G WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to th |
|
| August 9, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form F-1 (Form Type) TC Biopharm (Holdings) PLC (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be paid Equity Ordinary Shares, par value £0. |
|
| August 9, 2024 |
Exhibit 10.20 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of August , 2024, between TC BioPharm (Holdings) plc, a public limited company incorporated in Scotland pursuant to the Companies Act 2006, as amended with company number SC713098 (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors a |
|
| August 9, 2024 |
TC BIOPHARM (HOLDINGS) PLC Maxim 1, 2 Parklands Way Holytown, Motherwell ML1 4WR Scotland, United Kingdom August 9, 2024 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N. |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number 001-41231 TC BIOPHARM (HOLDINGS) PLC (Translation of registrant’s name into English) Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR Scotland, United K |
|
| August 8, 2024 |
Exhibit 99.1 TC BioPharm (Holdings) plc Maxim 1,2 Parklands Way, Maxim Park, Eurocentral, ML1 4WR Tel: 0141 433 7557 | Email: [email protected] August 5, 2024 VIA OVERNIGHT MAIL The Holders of Warrants to Purchase American Depositary Shares issued pursuant to the terms of that certain warrant agent agreement, dated February 10, 2022 (collectively, the “Holders”): To Whom It May Concern: You are |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number 001-41231 TC BIOPHARM (HOLDINGS) PLC (Translation of registrant’s name into English) Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR Scotland, United K |
|
| July 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2024 Commission File Number 001-41231 TC BIOPHARM (HOLDINGS) PLC (Translation of registrant’s name into English) Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR Scotland, United Kingdo |
|
| July 2, 2024 |
As filed with the Securities and Exchange Commission on July 2, 2024 As filed with the Securities and Exchange Commission on July 2, 2024 Registration Statement No. |
|
| July 2, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form F-1 (Form Type) TC Biopharm (Holdings) PLC (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be paid Equity Ordinary Shares, par value £0. |
|
| July 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number 001-41231 TC BIOPHARM (HOLDINGS) PLC (Translation of registrant’s name into English) Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR Scotland, United Kin |
|
| July 1, 2024 |
Exhibit 99.1 |
|
| July 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2024 Commission File Number 001-41231 TC BIOPHARM (HOLDINGS) PLC (Translation of registrant’s name into English) Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR Scotland, United Kingdo |
|
| July 1, 2024 |
Exhibit 99.1 TC BioPharm (Holdings) plc (a public limited incorporated and registered in Scotland under the Companies Act 2006 with registered number SC713098) Maxim 1,2 Parklands Way, Holytown, Motherwell, Scotland, ML1 4WR July 1, 2024 Notice of 2024 Annual General Meeting Dear Shareholder, 2024 Annual General Meeting of the shareholders of TC BioPharm (Holdings) plc (the “AGM” or “Meeting”) Our |
|
| June 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2024 TC Biopharm (Holdings) PLC (Exact name of registrant as specified in charter) Scotland 001-41231 N/A (State or other jurisdiction (Commission (IRS Employer of incorporat |
|
| June 26, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-280000 UP TO 3,500,000 AMERICAN DEPOSITARY SHARES REPRESENTING 70,000,000 ORDINARY SHARES TC BIOPHARM (HOLDINGS) PLC This prospectus relates to the offer and resale of series F ordinary share purchase warrants (the “Warrants”) to purchase up to 3,500,000 American Depositary Shares (the “ADSs”), which were issued by us pursuant to a letter agree |
|
| June 20, 2024 |
As filed with the Securities and Exchange Commission on June 20, 2024 As filed with the Securities and Exchange Commission on June 20, 2024 Registration Statement No. |
|
| June 20, 2024 |
TC BIOPHARM (HOLDINGS) PLC Maxim 1, 2 Parklands Way Holytown, Motherwell ML1 4WR Scotland, United Kingdom June 20, 2024 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N. |
|
| June 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| June 6, 2024 |
As filed with the Securities and Exchange Commission on June 6, 2024 As filed with the Securities and Exchange Commission on June 6, 2024 Registration Statement No. |
|
| June 6, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) TC Biopharm (Holdings) PLC (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1)(2) Proposed Maximum Offering Price Per Unit (3) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be paid Equity Ordinary Shares, par value £0. |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2024 TC Biopharm (Holdings) PLC (Exact name of registrant as specified in charter) Scotland 001-41231 N/A (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| May 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2024 TC Biopharm (Holdings) PLC (Exact name of registrant as specified in charter) Scotland 001-41231 N/A (State or other jurisdiction (Commission (IRS Employer of incorporati |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transaction period from to Commission File No. 001-41231 TC BIOPHARM (HOLDINGS) |
|
| May 8, 2024 |
Inducement Letter, dated May 6, 2024 Exhibit 10.1 TC BIOPHARM (HOLDINGS) PLC May 6, 2024 Holder of Series E Warrants to Purchase Ordinary Shares Represented by American Depositary Shares Re: Inducement Offer to Exercise Existing Warrants to Purchase Ordinary Shares Represented by American Depositary Shares Dear Holder: TC Biopharm (Holdings) PLC, a public limited company incorporated in Scotland pursuant to the Companies Act 2006 (th |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2024 TC Biopharm (Holdings) PLC (Exact name of registrant as specified in charter) Scotland 001-41231 N/A (State or other jurisdiction (Commission (IRS Employer of incorporatio |
|
| May 8, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| May 8, 2024 |
TC BioPharm Announces Exercise of Warrants for £3.1 Million Gross Proceeds Exhibit 99.1 TC BioPharm Announces Exercise of Warrants for £3.1 Million Gross Proceeds EDINBURGH, Scotland, May 6, 2024 /PRNewswire/ — TC BioPharm (Holdings) plc (“TC BioPharm” or the “Company”) (NASDAQ: TCBP), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the entry into a definitive agreement for the immediate exerc |
|
| May 6, 2024 |
Exhibit 99.1 TC BioPharm Announces Execution of Second Non-Binding Letter of Intent for Acquisition, Targeting Innovative CAR-T Therapies Acquisition target has established proof of concept data demonstrating the therapeutic potential for the treatment of multiple solid tumors EDINBURGH, Scotland, May 06, 2024 — TC BioPharm (Holdings) PLC (“TC BioPharm” or the “Company”) (NASDAQ: TCBP) a clinical |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2024 TC Biopharm (Holdings) PLC (Exact name of registrant as specified in charter) Scotland 001-41231 N/A (State or other jurisdiction (Commission (IRS Employer of incorporatio |
|
| April 29, 2024 |
Employment Agreement between the Registrant and Bryan Kobel, dated June 15, 2021 Exhibit 10.17 |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A ☒ AnNUAL REPORT pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2023 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transaction period from to Commission File No. 001-41231 TC BIOPHARM (HOLDINGS) PLC |
|
| April 29, 2024 |
Employment Agreement between the Registrant and Martin Thorp, dated March 1, 2019 Exhibit 10.18 |
|
| April 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2024 TC Biopharm (Holdings) PLC (Exact name of registrant as specified in charter) Scotland 001-41231 N/A (State or other jurisdiction (Commission (IRS Employer of incorporat |
|
| April 4, 2024 |
TCBP Announces Execution of Non-Binding Letter of Intent for Acquisition of NK Platform Technologies Exhibit 99.1 TCBP Announces Execution of Non-Binding Letter of Intent for Acquisition of NK Platform Technologies EDINBURGH, Scotland, April 04, 2024 - TC BioPharm (Holdings) PLC (“TC BioPharm” or the “Company”) (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced the execution of a non-b |
|
| April 1, 2024 |
Exhibit 97.1 TC BIOPHARM (HOLDINGS) PLC CLAWBACK POLICY I. Purpose and Scope The Board of Directors (the “Board”) of the Company believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board has therefore adopted this |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ AnNUAL REPORT pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2023 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transaction period from to Commission File No. 001-41231 TC BIOPHARM (HOLDINGS) PLC ( |
|
| March 19, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2024 TC Biopharm (Holdings) PLC (Exact name of registrant as specified in charter) Scotland 001-41231 N/A (State or other jurisdiction (Commission (IRS Employer of incorpora |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2024 TC Biopharm (Holdings) PLC (Exact name of registrant as specified in charter) Scotland 001-41231 N/A (State or other jurisdiction (Commission (IRS Employer of incorpora |
|
| March 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2024 TC Biopharm (Holdings) PLC (Exact name of registrant as specified in charter) Scotland 001-41231 N/A (State or other jurisdiction (Commission (IRS Employer of incorporat |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 TC Biopharm (Holdings) PLC (Exact name of registrant as specified in charter) Scotland 001-41231 N/A (State or other jurisdiction (Commission (IRS Employer of incorp |
|
| February 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive |
|
| February 14, 2024 |
Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2024 TC Biopharm (Holdings) PLC (Exact name of registrant as specified in charter) Scotland 001-41231 N/A (State or other jurisdiction (Commission (IRS Employer of incorp |
|
| February 14, 2024 |
TCBP Provides Shareholder Update and Highlights Upcoming Milestones Exhibit 99.1 TCBP Provides Shareholder Update and Highlights Upcoming Milestones ● Provides update on Preliminary Proxy Statement Filing ● Highlights Approximate $11.6 M cost-savings EDINBURGH, Scotland, February 14, 2024 — TC BioPharm (Holdings) PLC (“TC BioPharm” or the “Company”) (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies fo |
|
| February 14, 2024 |
SC 13G/A 1 armistice-tcbp123123a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* TC BIOPHARM (HOLDINGS) PLC (Name of Issuer) American Depositary Shares, each representing twenty Ordinary Share, nominal value £0.01 per share (Title of Class of Securities) 87807D400 (CUSIP Number) December 31, 2023 |
|
| February 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| January 29, 2024 |
SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* TC Biopharm (Holdings) plc (Name of Issuer) Ordinary Shares (Title of Class of Securities) 87807D202 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [ ] Rule 13d-1(c) [x] Rule 1 |
|
| January 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2024 (December 28, 2023) TC Biopharm (Holdings) PLC (Exact name of registrant as specified in charter) Scotland 001-41231 N/A (State or other jurisdiction (Commission (IRS |
|
| January 4, 2024 |
TC BioPharm Regains Compliance with Nasdaq Minimum Bid Price Requirement Exhibit 99.1 TC BioPharm Regains Compliance with Nasdaq Minimum Bid Price Requirement EDINBURGH, Scotland, January 04 2024 - TC BioPharm (Holdings) PLC (“TC BioPharm” or the “Company”) (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced that on January 2, 2024, the Company received a written notice from The N |
|
| December 21, 2023 |
Form of Warrant Amendment Agreement, dated December 19, 2023 Exhibit 10.5 December 18, 2023 Holder of Warrants to Purchase American Depositary Shares set forth on Exhibit A attached hereto Re: Amendment to Existing Warrants Dear Holder: Reference is hereby made to the offering on Form F-1 (File No. 333-274244) on or about the date hereof (the “Offering”) by TC BioPharm (Holdings) plc (the “Company”) of its American Depositary Shares, representing ordinary s |
|
| December 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number 001-41231 TC BIOPHARM (HOLDINGS) PLC (Translation of registrant’s name into English) Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR Scotland, United |
|
| December 21, 2023 |
Form of Placement Agent Warrant Exhibit 10.3 PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES TC BIOPHARM (HOLDINGS) PLC Warrant ADSs: Initial Exercise Date: December 21, 2023 THIS PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms an |
|
| December 21, 2023 |
TC BioPharm Announces Pricing of $3.5 Million Public Offering Exhibit 99.1 TC BioPharm Announces Pricing of $3.5 Million Public Offering EDINBURGH, Scotland, December 19, 2023 /PRNewswire/ — TC BioPharm (Holdings) plc (“TC BioPharm” or the “Company”) (NASDAQ: TCBP), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the pricing of a public offering of 1,750,000 of its American Deposi |
|
| December 21, 2023 |
Filed Pursuant to Rule 424(b)(4) Registration No. 333-274244 75,000 AMERICAN DEPOSITARY SHARES REPRESENTING 1,500,000 ORDINARY SHARES AND 1,675,000 PRE-FUNDED WARRANTS TO PURCHASE UP TO 1,675,000 AMERICAN DEPOSITARY SHARES AND 1,750,000 SERIES E WARRANTS TO PURCHASE UP TO 1,750,000 AMERICAN DEPOSITARY SHARES AND PLACEMENT AGENT WARRANTS TO PURCHASE UP TO 131,250 AMERICAN DEPOSITARY SHARES (and 1,6 |
|
| December 21, 2023 |
Exhibit 10.1 PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES TC BIOPHARM (HOLDINGS) PLC Warrant ADSs: 1,675,000 Initial Exercise Date: December 21, 2023 THIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms an |
|
| December 21, 2023 |
Exhibit 10.2 EXHIBIT A SERIES E WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES TC BIOPHARM (HOLDINGS) PLC Warrant ADSs: Initial Exercise Date: December 21, 2023 THIS SERIES E WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and su |
|
| December 21, 2023 |
Form of Securities Purchase Agreement for December 2023 Offering Exhibit 10.4 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 18, 2023, between TC BioPharm (Holdings) plc, a public limited company incorporated in Scotland pursuant to the Companies Act 2006, as amended with company number SC713098 (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successor |
|
| December 14, 2023 |
TC BIOPHARM (HOLDINGS) PLC Maxim 1, 2 Parklands Way Holytown, Motherwell ML1 4WR Scotland, United Kingdom December 14, 2023 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N. |
|
| December 14, 2023 |
As filed with the Securities and Exchange Commission on December 14, 2023 As filed with the Securities and Exchange Commission on December 14, 2023 Registration Statement No. |
|
| December 14, 2023 |
Exhibit 1.1 |
|
| December 13, 2023 |
As filed with the Securities and Exchange Commission on December 12, 2023 As filed with the Securities and Exchange Commission on December 12, 2023 Registration Statement No. |
|
| December 13, 2023 |
Form of Placement Agent Warrant for this Offering Exhibit 4.21 PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES TC BIOPHARM (HOLDINGS) PLC Warrant ADSs: Initial Exercise Date: , 2023 THIS PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject t |
|
| December 13, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form F-1 (Form Type) TC Biopharm (Holdings) PLC (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be paid Equity Ordinary Shares, par value £0. |
|
| December 13, 2023 |
Form of Securities Purchase Agreement for this Offering Exhibit 10.7 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2023, between TC BioPharm (Holdings) plc, a public limited company incorporated in Scotland pursuant to the Companies Act 2006, as amended with company number SC713098 (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assig |
|
| December 13, 2023 |
TC BioPharm Announces Plan to Implement ADS Ratio Change Exhibit 99.1 TC BioPharm Announces Plan to Implement ADS Ratio Change EDINBURGH, Scotland, December 13, 2023 - TC BioPharm (Holdings) PLC (“TC BioPharm” or the “Company”) (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, announced today that it will change its ratio of its American Depositary Shares (“ADSs”) to ordinary sh |
|
| December 13, 2023 |
Form of Pre-Funded Warrant for this Offering Exhibit 4.19 EXHIBIT B PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES TC BIOPHARM (HOLDINGS) PLC Warrant ADSs: Initial Exercise Date: , 2023 THIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject t |
|
| December 13, 2023 |
Form of Series E Ordinary Warrant for this Offering Exhibit 4.20 EXHIBIT A SERIES E WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES TC BIOPHARM (HOLDINGS) PLC Warrant ADSs: Initial Exercise Date: , 2023 THIS SERIES E WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to th |
|
| December 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number 001-41231 TC BIOPHARM (HOLDINGS) PLC (Translation of registrant’s name into English) Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR Scotland, United |
|
| November 8, 2023 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-274778 UP TO 12,942,813 AMERICAN DEPOSITARY SHARES REPRESENTING 12,942,813 ORDINARY SHARES TC BIOPHARM (HOLDINGS) PLC This prospectus relates to the offer and resale of series D purchase warrants (the “Series D Warrants”) to purchase up to 12,475,000 American Depositary Shares (the “ADSs”), which were issued by us pursuant to a letter agreement |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2023 Commission File Number: 001-41231 TC BioPharm (Holdings) plc (Translation of registrant’s name into English) Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR Scotland, Unite |
|
| November 2, 2023 |
As filed with the Securities and Exchange Commission on November 2, 2023 As filed with the Securities and Exchange Commission on November 2, 2023 Registration Statement No. |
|
| November 2, 2023 |
TC BIOPHARM (HOLDINGS) PLC Maxim 1, 2 Parklands Way Holytown, Motherwell ML1 4WR Scotland, United Kingdom November 2, 2023 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N. |
|
| November 2, 2023 |
INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Exhibit 99.1 INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Page Unaudited Condensed Consolidated Statements of Income and Total Comprehensive Income for the Six Months Ended June 30, 2023 and 2022 2 Unaudited Condensed Consolidated Statements of Financial Position as at June 30, 2023 and December 31, 2022 3 Unaudited Condensed Consolidated Statements of Changes in Equity f |
|
| November 2, 2023 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion and analysis of financial condition and operating results together with the information in our consolidated financial statements and the related notes to those statements included elsewhere in our Annual Report. We present our consolidated financial statements |
|
| September 29, 2023 |
Power of Attorney (included as part of the signature page of original filed Registration Statement) As filed with the Securities and Exchange Commission on September 29, 2023 Registration Statement No. |
|
| September 29, 2023 |
Form of Placement Agent Warrant issued in September 2023 Exhibit 4.19 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| September 29, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) TC Biopharm (Holdings) PLC (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1)(2) Proposed Maximum Offering Price Per Unit (3) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be paid Equity Ordinary Shares, par value £0. |
|
| September 1, 2023 |
UP TO 4,410,000 AMERICAN DEPOSITARY SHARES REPRESENTING 4,410,000 ORDINARY SHARES Filed pursuant to rule 424(b)(3) Registration Statement No. 333-268755 Prospectus Supplement (To the Prospectus dated December 23, 2022) UP TO 4,410,000 AMERICAN DEPOSITARY SHARES REPRESENTING 4,410,000 ORDINARY SHARES This prospectus supplement updates, supersedes and amends certain information contained in the prospectus dated December 23, 2022 (the “Original Prospectus”), relating to the offeri |
|
| September 1, 2023 |
UP TO 6,875,000 AMERICAN DEPOSITARY SHARES REPRESENTING 6,875,000 ORDINARY SHARES Filed pursuant to rule 424(b)(3) Registration Statement No. 333-270808 Prospectus Supplement (To the Prospectus dated March 27, 2023) UP TO 6,875,000 AMERICAN DEPOSITARY SHARES REPRESENTING 6,875,000 ORDINARY SHARES This prospectus supplement updates, supersedes and amends certain information contained in the prospectus dated March 27, 2023 (the “Original Prospectus”), relating to the offering of |
|
| August 31, 2023 |
Form of Inducement Letter, dated August 30, 2023 Exhibit 10.1 TC BIOPHARM (HOLDINGS) PLC August 30, 2023 Holder of Warrants to Purchase Ordinary Shares Represented by American Depositary Shares Re: Inducement Offer to Exercise Existing Warrants to Purchase Ordinary Shares Represented by American Depositary Shares Dear Holder: TC Biopharm (Holdings) PLC, a public limited company incorporated in Scotland pursuant to the Companies Act 2006 (the “Co |
|
| August 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number 001-41231 TC BIOPHARM (HOLDINGS) PLC (Translation of registrant’s name into English) Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR Scotland, United K |
|
| August 31, 2023 |
Form of Series D Ordinary Warrant Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| August 28, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form F-1 (Form Type) TC Biopharm (Holdings) PLC (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be paid Equity Ordinary Shares, par value £0. |
|
| August 28, 2023 |
Power of Attorney (included as part of the signature page of original filed Registration Statement) As filed with the Securities and Exchange Commission on August 28, 2023 Registration Statement No. |
|
| August 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number 001-41231 TC BIOPHARM (HOLDINGS) PLC (Translation of registrant’s name into English) Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR Scotland, United K |
|
| July 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number 001-41231 TC BIOPHARM (HOLDINGS) PLC (Translation of registrant’s name into English) Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR Scotland, United Kin |
|
| July 24, 2023 |
Warrant Amendment Agreement, dated July 10, 2023 Exhibit 10.1 |
|
| July 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number 001-41231 TC BIOPHARM (HOLDINGS) PLC (Translation of registrant’s name into English) Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR Scotland, United Kin |
|
| July 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 July 10, 2023 Commission File Number 001-41231 TC BIOPHARM (HOLDINGS) PLC (Translation of registrant’s name into English) Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR Scotland, United Kingdom +44 (0) |
|
| June 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2023 Commission File Number 001-41231 TC BIOPHARM (HOLDINGS) PLC (Translation of registrant’s name into English) Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR Scotland, United Kingdo |
|
| June 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number 001-41231 TC BIOPHARM (HOLDINGS) PLC (Translation of registrant’s name into English) Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR Scotland, United Kin |
|
| June 7, 2023 |
Exhibit 99.2 TC BIOPHARM (HOLDINGS) PLC Company number: SC713098 (the “Company”) PROXY FORM for use at the annual general meeting of the Company to be held at Maxim 1, 2 Parklands Way, Holytown, Motherwell, ML1 4WR, United Kingdom on 29 June 2023 at 15:00 (UK time) (the “AGM”) PLEASE READ THE NOTES BELOW BEFORE COMPLETING THIS PROXY FORM IN BLACK INK AND BLOCK CAPITALS We, being a member of the Co |
|
| June 7, 2023 |
Exhibit 99.4 Dear ADS holder, We are writing to inform you that the 2023 annual general meeting of the shareholders of TC BioPharm (Holdings) plc (the “Company”) will be held on Thursday, June 29, 2023 at 15:00 UK time (10:00 Eastern Time) (the “AGM”). Enclosed please find your voting instruction card. Information regarding the AGM, including the Notice of AGM (the “AGM Notice”), may be accessed t |
|
| June 7, 2023 |
Voting Instruction Form for holders of American Depositary Shares. Exhibit 99.3 |
|
| June 7, 2023 |
Exhibit 99.1 TC BIOPHARM (HOLDINGS) PLC Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR United Kingdom (Incorporated and registered in Scotland with registered number SC713098) THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to the action to be taken, please seek your own financial advice from your stockbroker, solicitor, accountant or other appr |
|
| June 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2023 Commission File Number 001-41231 TC BIOPHARM (HOLDINGS) PLC (Translation of registrant’s name into English) Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR Scotland, United Kingdo |
|
| May 1, 2023 |
Exhibit 13.1 Certification by the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report on Form 20-F of TC BioPharm (Holdings) plc (the “Company”) for the fiscal year ended December 31, 2022 as filed with the Securities and Exchange Commission on the d |
|
| May 1, 2023 |
Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Bryan Kobel, certify that: 1. I have reviewed this annual report on Form 20-F of TC BioPharm (Holdings) plc (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement |
|
| May 1, 2023 |
Form of Indemnification Agreement Exhibit 4.16 INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made as of the day of , 2023 and between TC BioPharm (Holdings) plc, a company formed under the laws of Scotland, United Kingdom (“Company”), and (the “Indemnitee”). RECITALS A. The Indemnitee is to serve as an [officer, director, employee and/or agent] of the Company and/or the Company’s subsidiaries and the Co |
|
| May 1, 2023 |
Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Martin Thorp, certify that: 1. I have reviewed this annual report on Form 20-F of TC BioPharm (Holdings) plc (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statemen |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT O |
|
| April 11, 2023 |
UP TO 4,410,000 AMERICAN DEPOSITARY SHARES REPRESENTING 4,410,000 ORDINARY SHARES Filed pursuant to rule 424(b)(3) Registration Statement No. 333-268755 Prospectus Supplement (To the Prospectus dated December 23, 2022) UP TO 4,410,000 AMERICAN DEPOSITARY SHARES REPRESENTING 4,410,000 ORDINARY SHARES This prospectus supplement updates, supersedes and amends certain information contained in the prospectus dated December 23, 2022 (the “Original Prospectus”), relating to the offeri |
|
| March 30, 2023 |
Form of Series C Ordinary Warrant Exhibit 10.2 SERIES C WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES TC BIOPHARM (HOLDINGS) PLC Warrant ADSs: Issuance Date: March 30, 2023 Initial Exercise Date: March 30, 2023 THIS SERIES C WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon |
|
| March 30, 2023 |
Exhibit 10.1 PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES TC BIOPHARM (HOLDINGS) PLC Warrant ADSs: Issuance Date: March 30, 2023 Initial Exercise Date: March 30, 2023 THIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, |
|
| March 30, 2023 |
Form of Placement Agent Warrant Exhibit 10.3 PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES TC BIOPHARM (HOLDINGS) PLC Warrant ADSs: Issuance Date: , 2023 Initial Exercise Date:, 2023 THIS PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon th |
|
| March 30, 2023 |
Warrant Amendment Agreement, dated March 27, 2023 Exhibit 10.5 March 27, 2023 Holder of Warrants to Purchase American Depositary Shares issued on November 30, 2022. Re: Amendment to Existing Warrants Dear Holder: Reference is hereby made to the offering on Form F-1 (File No. 333-270808) on or about the date hereof (the “Offering”) by TC BioPharm (Holdings) plc (the “Company”) American depositary shares, representing ordinary shares, par value $0. |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number 001-41231 TC BIOPHARM (HOLDINGS) PLC (Translation of registrant’s name into English) Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR Scotland, United Ki |
|
| March 30, 2023 |
Warrant Amendment Agreement, dated March 27, 2023 Exhibit 10.4 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 27, 2023, between TC BIOPHARM (HOLDINGS) PLC, a public limited company incorporated in Scotland pursuant to the Companies Act 2006, as amended with company number SC713098 (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors a |
|
| March 30, 2023 |
TC BioPharm Announces Pricing of $5.5 Million Public Offering Exhibit 99.1 TC BioPharm Announces Pricing of $5.5 Million Public Offering EDINBURGH, Scotland, March 28, 2023 /PRNewswire/ — TC BioPharm (Holdings) PLC (“TC BioPharm” or the “Company”) (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the pricing of a public offering of 3,437,500 of its American Depositary |
|
| March 29, 2023 |
424B4 1 form424b4.htm Filed pursuant to rule 424(b)(4) Registration Statement No. 333-270808 215,000 AMERICAN DEPOSITARY SHARES REPRESENTING UP TO 215,000 ORDINARY SHARES AND 3,222,500 PRE-FUNDED WARRANTS TO PURCHASE UP TO 3,222,500 AMERICAN DEPOSITARY SHARES AND 3,437,500 SERIES C WARRANTS TO PURCHASE UP TO 3,437,500 AMERICAN DEPOSITARY SHARES AND PLACEMENT AGENT WARRANTS TO PURCHASE UP TO 257,81 |
|
| March 27, 2023 |
As filed with the Securities and Exchange Commission on March 27, 2023 As filed with the Securities and Exchange Commission on March 27, 2023 Registration Statement No. |
|
| March 23, 2023 |
Form of Placement Agent Warrant Exhibit 4.16 PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES TC BIOPHARM (HOLDINGS) PLC Warrant ADSs: Issuance Date: , 2023 Initial Exercise Date:, 2023 THIS PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon th |
|
| March 23, 2023 |
As filed with the Securities and Exchange Commission on March 23, 2023 As filed with the Securities and Exchange Commission on March 23, 2023 Registration Statement No. |
|
| March 23, 2023 |
TC BIOPHARM (HOLDINGS) PLC Maxim 1, 2 Parklands Way Holytown, Motherwell ML1 4WR Scotland, United Kingdom March 23, 2023 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N. |
|
| March 23, 2023 |
Form of Securities Purchase Agreement Exhibit 10.3 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March , 2023, between TC BIOPHARM (HOLDINGS) PLC, a public limited company incorporated in Scotland pursuant to the Companies Act 2006, as amended with company number SC713098 (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and |
|
| March 23, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form F-1 (Form Type) TC Biopharm (Holdings) PLC (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be paid Equity Ordinary Shares, par value £0. |
|
| March 23, 2023 |
Exhibit 4.15 PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES TC BIOPHARM (HOLDINGS) PLC Warrant ADSs: Issuance Date: , 2023 Initial Exercise Date:, 2023 THIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms an |
|
| March 23, 2023 |
Form of Series C Ordinary Warrant Exhibit 4.17 SERIES C WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES TC BIOPHARM (HOLDINGS) PLC Warrant ADSs: Issuance Date: , 2023 Initial Exercise Date:, 2023 THIS SERIES C WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and su |
|
| February 28, 2023 |
TCBP / TC BioPharm (Holdings) plc - ADR / Nipro Corp - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 TC BioPharm (Holdings) plc (Name of Issuer) ADSs / Ordinary Shares (Title of Class of Securities) 87807D202 (CUSIP Number) Nipro Corporation Division of New Business Development 9-3, Honjo-nishi 3-chome Kita-ku, Osaka 531-8510 Japan Attention: Kimihito Minoura 81-(0)6-6375 |
|
| February 14, 2023 |
TCBP / TC BioPharm (Holdings) Ltd / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 10, 2023 |
As confidentially submitted to the Securities and Exchange Commission on February 9, 2023 As confidentially submitted to the Securities and Exchange Commission on February 9, 2023 Registration Statement No. |
|
| January 30, 2023 |
TCBP / TC BioPharm (Holdings) Ltd / MEDINET Co., Ltd. Passive Investment SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* TC Biopharm (Holdings) plc (Name of Issuer) Ordinary Shares (Title of Class of Securities) 87807D202 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [ ] Rule 13d-1(c) [x] Rule 13 |
|
| January 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File Number 001-41231 TC BIOPHARM (HOLDINGS) PLC (Translation of registrant’s name into English) Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR Scotland, United |
|
| January 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File Number 001-41231 TC BIOPHARM (HOLDINGS) PLC (Translation of registrant’s name into English) Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR Scotland, United |
|
| January 11, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-101) (Amendment No. 1) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13D-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13D-2(a) TC BioPharm (Holdings) plc (Name of Issuer) ADSs / Ordinary Shares (Title of Class of Securities) 87807D202 (CUSIP Number) Thomas Nicholls Renaissance Capital Partners |
|
| December 27, 2022 |
Filed pursuant to rule 424(b)(3) Registration Statement No. 333-268755 UP TO 4,410,000 AMERICAN DEPOSITARY SHARES REPRESENTING 4,410,000 ORDINARY SHARES TC BIOPHARM (HOLDINGS) PLC This prospectus relates to the offer and resale of an aggregate 155,000 American Depositary Shares (the “ADSs”), or ADSs representing ordinary shares, pre-funded warrants to purchase up to 1,315,000 ADS (the “Pre-Funded |
|
| December 21, 2022 |
TC BIOPHARM (HOLDINGS) PLC Maxim 1, 2 Parklands Way Holytown, Motherwell ML1 4WR Scotland, United Kingdom December 21, 2022 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N. |
|
| December 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2022 Commission File Number: 001-41231 TC BioPharm (Holdings) plc (Translation of registrant’s name into English) Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR Scotland, Unite |
|
| December 12, 2022 |
TC BioPharm Reports First Half 2022 Financial Results and Provides Shareholder Update Exhibit 99.3 TC BioPharm Reports First Half 2022 Financial Results and Provides Shareholder Update ● Dosed first three patients within Phase 2b clinical trial of OmnImmune®, an allogeneic unmodified cell therapy focused on treating Acute Myeloid Leukemia (AML). ● Complete and near complete responses (morphologic leukemia-free state) observed with OmnImmune® starting at lowest dose level in Phase 1 |
|
| December 12, 2022 |
EX-FILING FEES 5 ex107.htm CALCULATION OF FILING FEE TABLES Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) TC Biopharm (Holdings) PLC (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1)(2) Proposed Maximum Offering Price Per Unit (3) Maximum Aggr |
|
| December 12, 2022 |
As filed with the Securities and Exchange Commission on December 12, 2022 As filed with the Securities and Exchange Commission on December 12, 2022 Registration Statement No. |
|
| December 12, 2022 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion and analysis of financial condition and operating results together with the information in our consolidated financial statements and the related notes to those statements included elsewhere in our Annual Report. We present our consolidated financial statements |
|
| December 12, 2022 |
INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Exhibit 99.1 INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Page Unaudited Condensed Consolidated Statements of Income/(Loss) and Total Comprehensive Income/(Loss) for the Six Months Ended June 30, 2022 and 2021 2 Unaudited Condensed Consolidated Statements of Financial Position as at June 30, 2022 and December 31, 2021 3 Unaudited Condensed Consolidated Statements of Chang |
|
| November 30, 2022 |
Form of Series A and Series B Ordinary Warrant Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| November 30, 2022 |
Form of Registration Rights Agreement for Nov 2022 Private Placement Exhibit 10.5 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of November 27, 2022, between TC BIOPHARM (HOLDINGS) PLC, a public limited company incorporated in Scotland pursuant to the Companies Act 2006, as amended with company number SC713098 (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, |
|
| November 30, 2022 |
Form of Placement Agent Warrant Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| November 30, 2022 |
Form of Securities Purchase Agreement for Nov 2022 Private Placement Exhibit 10.4 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”), dated as of November 27, 2022, is between TC BIOPHARM (HOLDINGS) PLC, a public limited company incorporated in Scotland pursuant to the Companies Act 2006, as amended with company number SC713098 (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successo |
|
| November 30, 2022 |
Exhibit 10.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| November 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number 001-41231 TC BIOPHARM (HOLDINGS) PLC (Translation of registrant’s name into English) Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR Scotland, United |
|
| November 22, 2022 |
Communication from BNY Mellon to ADS holders Exhibit 1.1 |
|
| November 22, 2022 |
Warrant repricing notice to warrant holders Exhibit 1.2 TC BioPharm (Holdings) plc Maxim 1,2 Parklands Way, Maxim Park, Eurocentral, ML1 4WR Tel: 0141 433 7557 | Email: [email protected] November 21, 2022 VIA OVERNIGHT MAIL The Holders of Warrants to Purchase American Depositary Shares issued pursuant to the terms of that certain warrant agent agreement, dated February 10, 2022 (collectively, the “Holders”): To Whom It May Concern: You ar |
|
| November 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number 001-41231 TC BIOPHARM (HOLDINGS) PLC (Translation of registrant’s name into English) Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR Scotland, United |
|
| November 18, 2022 |
Letter of Ernst & Young LLP, dated November 18, 2022 Exhibit 16.1 November 18, 2022 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: We have read Form 6-K dated November 18, 2022, of TC BioPharm (Holdings) plc and are in agreement with the statements contained in paragraphs 1, 2 and 3 on page 2 therein. We have no basis to agree or disagree with other statements of the registrant contained therein. /s/ |
|
| November 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number 001-41231 TC BIOPHARM (HOLDINGS) PLC (Translation of registrant’s name into English) Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR Scotland, United |
|
| November 16, 2022 |
6-K 1 form6-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number 001-41231 TC BIOPHARM (HOLDINGS) PLC (Translation of registrant’s name into English) Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4W |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number 001-41231 TC BIOPHARM (HOLDINGS) PLC (Translation of registrant?s name into English) Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR Scotland, United |
|
| October 6, 2022 |
Exhibit 99.3 |
|
| October 6, 2022 |
Exhibit 99.1 THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about the contents of this document or as to what action you should take, you should consult your stockbroker, bank manager, solicitor, accountant or other independent financial adviser duly authorised under the Financial Services and Markets Act 2000 (as amended) if you are a resident of the Uni |
|
| October 6, 2022 |
Exhibit 99.2 |
|
| October 6, 2022 |
6-K 1 form6-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2022 Commission File Number 001-41231 TC BIOPHARM (HOLDINGS) PLC (Translation of registrant’s name into English) Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR |
|
| July 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2022 Commission File Number 001-41231 TC BIOPHARM (HOLDINGS) PLC (Translation of registrant?s name into English) Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR Scotland, United Kin |
|
| July 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2022 Commission File Number 001-41231 TC BIOPHARM (HOLDINGS) PLC (Translation of registrant?s name into English) Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR Scotland, United Kin |
|
| June 3, 2022 |
6-K 1 form6-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 Commission File Number 001-41231 TC BIOPHARM (HOLDINGS) PLC (Translation of registrant’s name into English) Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR Sc |
|
| June 3, 2022 |
424B1 1 form424b1.htm Filed pursuant to rule 424(b)(1) Registration Statement No. 333-265159 10,000,000 AMERICAN DEPOSITARY SHARES REPRESENTING 10,000,000 ORDINARY SHARES TC BIOPHARM (HOLDINGS) PLC This is a public offering of American depositary shares, or ADSs representing ordinary shares, of TC BioPharm (Holdings) PLC, or TCB. TCB is offering 10,000,000 ADSs. Each ADS represents one of our ordi |
|
| May 31, 2022 |
EXHIBIT 107 Calculation of Filing Fee Table F-1 (Form Type) TC BioPharm (Holdings) plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Share(1) Maximum Aggregate Offering Price(1)(2) Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees Previously Paid Equity Ordinary shares, ?0. |
|
| May 31, 2022 |
EF Hutton, division of Benchmark Investments, LLC 590 Madison Avenue, 39th Floor New York, NY 10022 CORRESP 1 filename1.htm EF Hutton, division of Benchmark Investments, LLC 590 Madison Avenue, 39th Floor New York, NY 10022 May 31, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Ms. Christine Westbrook Re: TC BioPharm (Holdings) plc Registration Statement on Form F-1, File No. 333-265159 REQUEST FOR ACCELER |
|
| May 31, 2022 |
TC BIOPHARM (HOLDINGS) PLC Maxim 1, 2 Parklands Way Holytown, Motherwell ML1 4WR Scotland, United Kingdom May 31, 2022 VIA EDGAR U. |
|
| May 31, 2022 |
As filed with the Securities and Exchange Commission on May 31, 2022. As filed with the Securities and Exchange Commission on May 31, 2022. Registration No. 333-265159 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM F-1 REGISTRATION STATEMENT UNDER SECURITIES ACT OF 1933 TC BIOPHARM (HOLDINGS) PLC (Exact name of registrant as specified in its charter) Scotland 8731 Not Applicable (State or other jurisdiction of (Primar |
|
| May 31, 2022 |
Exhibit 1.1 UNDERWRITING AGREEMENT between TC BIOPHARM (HOLDINGS) PLC and EF HUTTON, division of Benchmark Investments, LLC, as Representative of the Several Underwriters UNDERWRITING AGREEMENT between TC BIOPHARM (HOLDINGS) PLC and EF HUTTON division of Benchmark Investments, LLC, as Representative of the Several Underwriters New York, New York June , 2022 EF Hutton, division of Benchmark Investm |
|
| May 26, 2022 |
EF Hutton, division of Benchmark Investments, LLC 590 Madison Avenue, 39th Floor New York, NY 10022 EF Hutton, division of Benchmark Investments, LLC 590 Madison Avenue, 39th Floor New York, NY 10022 May 26, 2022 VIA EDGAR U. |
|
| May 26, 2022 |
TC BIOPHARM (HOLDINGS) PLC Maxim 1, 2 Parklands Way Holytown, Motherwell ML1 4WR Scotland, United Kingdom May 26, 2022 VIA EDGAR U. |
|
| May 24, 2022 |
Exhibit 1.1 UNDERWRITING AGREEMENT between TC BIOPHARM (HOLDINGS) PLC and EF HUTTON, division of Benchmark Investments, LLC, as Representative of the Several Underwriters UNDERWRITING AGREEMENT between TC BIOPHARM (HOLDINGS) PLC and EF HUTTON division of Benchmark Investments, LLC, as Representative of the Several Underwriters New York, New York May , 2022 EF Hutton, division of Benchmark Investme |
|
| May 24, 2022 |
As filed with the Securities and Exchange Commission on May 23, 2022. As filed with the Securities and Exchange Commission on May 23, 2022. Registration No. 333-[xxxxxxxx] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER SECURITIES ACT OF 1933 TC BIOPHARM (HOLDINGS) PLC (Exact name of registrant as specified in its charter) Scotland 8731 Not Applicable (State or other jurisdiction of (Primary Standard Indu |
|
| May 24, 2022 |
EX-FILING FEES 5 ex-107.htm EXHIBIT 107 Calculation of Filing Fee Table F-1 (Form Type) TC BioPharm (Holdings) plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Share(1) Maximum Aggregate Offering Price(1)(2) |
|
| May 23, 2022 |
EF Hutton, division of Benchmark Investments, LLC 590 Madison Avenue, 39th Floor New York, NY 10022 CORRESP 1 filename1.htm EF Hutton, division of Benchmark Investments, LLC 590 Madison Avenue, 39th Floor New York, NY 10022 May 23, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Ms. Christine Westbrook Re: TC BioPharm (Holdings) plc Registration Statement on Form F-1, File No. 333-265159 REQUEST FOR ACCELER |
|
| May 23, 2022 |
TC BIOPHARM (HOLDINGS) PLC Maxim 1, 2 Parklands Way Holytown, Motherwell ML1 4WR Scotland, United Kingdom May 23, 2022 VIA EDGAR U. |
|
| May 17, 2022 |
As confidentially submitted to the Securities and Exchange Commission on May 17, 2022. DRS 1 filename1.htm As confidentially submitted to the Securities and Exchange Commission on May 17, 2022. Registration No. 333-[xxxxxxxx] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER SECURITIES ACT OF 1933 TC BIOPHARM (HOLDINGS) PLC (Exact name of registrant as specified in its charter) Scotland 8731 Not Applicable (State or other j |
|
| May 13, 2022 |
Description of Securities of Registrant Exhibit 4.11 Description of Securities Share Capital ? Ordinary Shares Our share capital currently consists of ordinary shares. We may issue shares with such rights or restrictions as may be determined by ordinary resolution, including shares which are to be redeemed, or are liable to be redeemed at our option or the option of the holder of such shares. Voting The shareholders have the right to re |
|
| May 13, 2022 |
Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Bryan Kobel, certify that: 1. I have reviewed this annual report on Form 20-F of TC BioPharm (Holdings) plc (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement |
|
| May 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT O |
|
| May 13, 2022 |
Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Martin Thorp, certify that: 1. I have reviewed this annual report on Form 20-F of TC BioPharm (Holdings) plc (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statemen |
|
| May 13, 2022 |
Exhibit 13.1 Certification by the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report on Form 20-F of TC BioPharm (Holdings) plc (the “Company”) for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission on the d |
|
| May 13, 2022 |
Form of Deed of Indemnity for directors and officer Exhibit 4.10 INDEMNIFICATION AGREEMENT This Indemnification Agreement (?Agreement?) is made as of the day of , 2022 and between TC BioPharm (Holdings) plc, a company formed under the laws of Scotland, United Kingdom (?Company?), and (the ?Indemnitee?). RECITALS A. The Indemnitee is to serve as an [officer, director, employee and/or agent] of the Company and/or the Company?s subsidiaries and the Co |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NT 20-F 1 formnt20-f.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC FILE NUMBER 001-41231 FORM 12b-25 NOTIFICATION OF LATE FILING CUSIP NUMBER 87807D 103 87807D 111 (Check One): ☐ Form 10-K ☒ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2021 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ |
|
| April 27, 2022 |
Exhibit 99.1 AGREEMENT AS TO JOINT FILING In accordance with Rule 13d-1(k) under the Securities and Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing on behalf of each of them of a statement on Schedule 13D, and any amendments thereto, with respect to the Ordinary Shares, par value £0.01 per share of TC BioPharm (Holdings) plc, and that this agreement be included a |
|
| April 27, 2022 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13D-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13D-2(a) TC BioPharm (Holdings) plc (Name of Issuer) ADSs / Ordinary Shares (Title of Class of Securities) 87807D 103 (ISIN or CUSIP Number) Thomas Nicholls Renaissance Capital Partners Limited 4 |
|
| March 17, 2022 |
TCBP / TC BioPharm (Holdings) Ltd / Alta Partners LLC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) I. INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )* TC BIOPHARM (HOLDINGS) PLC (Name of Issuer) Ordinary Shares, ?0.01 par value (Title of Class of Securities) 87807D103 (CUSIP Number) February 11, 2022 |
|
| March 8, 2022 |
As filed with the Securities and Exchange Commission on March 8, 2022. As filed with the Securities and Exchange Commission on March 8, 2022. Registration No. 333-260492 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST EFFECTIVE AMENDMENT NO. 1 TO FORM F-1 REGISTRATION STATEMENT UNDER SECURITIES ACT OF 1933 TC BIOPHARM (HOLDINGS) PLC (Exact name of registrant as specified in its charter) Scotland 8731 Not Applicable (State or other jurisdi |
|
| March 8, 2022 |
Underwriting Agreement, dated February 10, 2022 * Exhibit 1.1 UNDERWRITING AGREEMENT between TC BIOPHARM (HOLDINGS) PLC and EF HUTTON division of Benchmark Investments, LLC, as Representative of the Several Underwriters New York, New York February 10, 2022 EF Hutton, division of Benchmark Investments, LLC as Representative of the several Underwriters named on Schedule 1 hereto 590 Madison Avenue, 39th Floor New York, New York 10022 Ladies and Gen |
|
| March 8, 2022 |
Form of Warrant Certificate (included in Exhibit 2.3) EX-4.4 3 ex4-4.htm Exhibit 4.4 WARRANT AGENT AGREEMENT WARRANT AGENT AGREEMENT (this “Warrant Agreement”) dated as of February 10, 2022 (the “Issuance Date”) between TC BioPharm (Holdings) plc, a company incorporated in Scotland, under the law of the United Kingdom (the “Company”), and Computershare Inc., a Delaware corporation (“Computershare”), and its wholly owned subsidiary, Computershare Trus |
